Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMBOLEX vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Prophylaxis of deep vein thrombosis (DVT) in surgical patients,Treatment of DVT,Treatment of pulmonary embolism,Prophylaxis of thromboembolic complications in medical patients
Mild to moderate pain,Pain accompanied by fever
Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
2-3 hours (terminal half-life in healthy adults); prolonged in hepatic impairment and elderly.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Primarily metabolized by desulfation and depolymerization in the liver; partial renal excretion.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Renal: ~50% (10% as unchanged drug, 40% as inactive metabolites); Biliary/fecal: ~50% (primarily as metabolites).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
99% (primarily to albumin).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
0.1-0.2 L/kg (low, indicating limited extravascular distribution primarily in blood).
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: 60-75% (first-pass metabolism); Rectal: ~80%. IV: 100%.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No specific dose adjustment for renal impairment; use caution in severe renal impairment (Cr Cl <30 m L/min) due to increased bleeding risk.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No specific adjustment for Child-Pugh class; use caution in severe hepatic impairment due to coagulopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Not established; use only if benefit outweighs risk, with careful monitoring.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Increased risk of bleeding; consider lower doses and shorter infusion durations. No specific dosing guidelines; use clinical judgment.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Spinal or epidural hematomas may occur in patients receiving low molecular weight heparins and undergoing neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Risk of spinal/epidural hematoma with neuraxial interventions; increased risk of bleeding; heparin-induced thrombocytopenia (HIT); renal impairment; elderly; pregnancy.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to heparin or pork products,Active major bleeding,History of heparin-induced thrombocytopenia (HIT),Known bleeding disorder,Severe uncontrolled hypertension
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Avoid alcohol; may increase risk of GI bleeding. No significant food interactions beyond GI irritation; taking with food may slow absorption but does not affect efficacy.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Embolex (certoparin) is a low molecular weight heparin; no evidence of teratogenicity in animal studies. First trimester: Use only if clearly needed; no known fetal risk. Second and third trimesters: May be used; risk of bleeding in mother/fetus. Avoid near delivery due to risk of maternal hemorrhage and epidural hematoma.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Excretion into human milk is unknown; low molecular weight heparins are unlikely to be absorbed by infant. M/P ratio not available. Use with caution in breastfeeding women.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Pregnancy increases plasma volume and renal clearance; may require higher doses to achieve therapeutic anti-Xa levels. Monitor anti-Xa levels and adjust dose accordingly. No standard dose adjustment; individualize based on weight and anti-Xa monitoring.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
EMBOLEX (meloxicam) is an NSAID with preferential COX-2 inhibition; use lowest effective dose for shortest duration to minimize GI and cardiovascular risks. Contraindicated in patients with active peptic ulcer disease, recent GI bleeding, or history of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs. Monitor renal function in elderly, dehydrated, or those on diuretics/ACE inhibitors. Not recommended for perioperative pain in CABG surgery.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, coffee-ground vomit) or cardiovascular symptoms (chest pain, shortness of breath) immediately.,Do not take with other NSAIDs (including over-the-counter ibuprofen or naproxen).,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMBOLEX vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
EMBOLEX is a Low Molecular Weight Heparin that works by Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMBOLEX and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMBOLEX is: Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMBOLEX and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMBOLEX is classified as Category C. Embolex (certoparin) is a low molecular weight heparin; no evidence of teratogenicity in animal studies. First trimester: Use only if clearly needed; no known fetal risk. Second an. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.